fda advisory_committee_meeting
saveAstraZeneca Plc — camizestrant (FDA Advisory Committee Meeting)
community read0 votes
Therapy area: Oncology. Indication: Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Data sources
globaldata
Found something off?
same company · ±60 days · 6
- phase 1 2 completionCALQUENCE: AstraZeneca Plc — Calquence (Phase I/II Trial Completion)Apr 30, 2026
- fda advisory committee meetingcapivasertib: AstraZeneca Plc — capivasertib (FDA Advisory Committee Meeting)Apr 30, 2026
- phase 2 completiontozorakimab: AstraZeneca Plc — tozorakimab (Phase II Trial Completion)Apr 30, 2026
- phase 3 completiondurvalumab: AstraZeneca Plc — durvalumab (Phase III Trial Completion)Apr 29, 2026
- earningsASTRAZENECA PLC earningsApr 29, 2026
- approvaleplontersen sodium: WAINUA (AUTOINJECTOR) (EPLONTERSEN SODIUM) — FDA approvalApr 15, 2026
related news · 4
- onclivePoll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026
- oncliveASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
- biopharma diveSummit’s ‘self-inflicted’ stumble; Esperion’s take-private deal
- endpointsFDA's oncology advisors vote against 'new paradigm' in AstraZeneca trial
comments(0)
5-min edit window · permanent after that